IN2014MN02598A - - Google Patents
Info
- Publication number
- IN2014MN02598A IN2014MN02598A IN2598MUN2014A IN2014MN02598A IN 2014MN02598 A IN2014MN02598 A IN 2014MN02598A IN 2598MUN2014 A IN2598MUN2014 A IN 2598MUN2014A IN 2014MN02598 A IN2014MN02598 A IN 2014MN02598A
- Authority
- IN
- India
- Prior art keywords
- compounds
- disclosed
- formula
- methods
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261667806P | 2012-07-03 | 2012-07-03 | |
US201361798524P | 2013-03-15 | 2013-03-15 | |
PCT/US2013/049119 WO2014008285A1 (fr) | 2012-07-03 | 2013-07-02 | Inhibiteurs du virus de l'hépatite c |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014MN02598A true IN2014MN02598A (fr) | 2015-07-24 |
Family
ID=48803614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2598MUN2014 IN2014MN02598A (fr) | 2012-07-03 | 2013-07-02 |
Country Status (41)
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲mPGES-1抑制劑之***酮化合物 |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
MA37992B1 (fr) | 2012-10-19 | 2018-09-28 | Bristol Myers Squibb Co | Composes inhibiteurs de protéase ns3 pour une utilisation dans le traitement de l’infection par le virus de l'hépatite c. |
US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914613B1 (fr) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2914614B1 (fr) | 2012-11-05 | 2017-08-16 | Bristol-Myers Squibb Company | Inhibiteurs du virus de l'hépatite c |
CN105748499B (zh) | 2013-01-31 | 2018-12-28 | 吉利德制药有限责任公司 | 两个抗病毒化合物的联用制剂 |
US9580463B2 (en) | 2013-03-07 | 2017-02-28 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US9617310B2 (en) * | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
MX2016002185A (es) | 2013-08-27 | 2016-06-06 | Gilead Pharmasset Llc | Formulacion combinada de dos compuestos antivirales. |
CN111320610B (zh) | 2013-12-23 | 2023-06-06 | 吉利德科学公司 | 大环hcv ns3抑制三肽的合成 |
JP6568541B2 (ja) * | 2013-12-23 | 2019-08-28 | ギリアド ファーマセット エルエルシー | 大環状hcv ns3阻害トリペプチドの結晶形態 |
US10059969B1 (en) | 2014-10-03 | 2018-08-28 | Abbvie Inc. | Process for the preparation of (S)-2-amino-non-8-enoic acid |
US20190022116A1 (en) | 2014-12-26 | 2019-01-24 | Emory University | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto |
CN107250097B (zh) * | 2015-02-16 | 2020-08-07 | 中央硝子株式会社 | 含氟α-酮羧酸酯类的实用制造方法 |
WO2017184670A2 (fr) | 2016-04-22 | 2017-10-26 | Gilead Sciences, Inc. | Méthodes de traitement d'infections à virus zika |
EP3454856A4 (fr) | 2016-05-10 | 2019-12-25 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
EP3455218A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles |
SG11201809893WA (en) | 2016-05-27 | 2018-12-28 | Gilead Sciences Inc | Methods for treating hepatitis b virus infections using ns5a, ns5b or ns3 inhibitors |
BR102017011025A2 (pt) * | 2016-06-02 | 2017-12-19 | Gilead Pharmasset Llc | Formulation of combination of three antiviral compounds |
JOP20190052A1 (ar) | 2016-09-22 | 2019-03-21 | Astrazeneca Ab | 5-[2-(بيريدين-2-يلامينو )-3،1 ثيازول-5-يال]-3،2 – ثنائي هيدرو- 1h- إيزوإندول 1--مشتق واحد واستخدامها كمثبطات مزدوجة للدلتا وغاما فوسفاتيديلينوسيتول 3-كيناز |
WO2018144681A1 (fr) * | 2017-02-01 | 2018-08-09 | Abbvie Inc. | Procédés enzymatiques pour la préparation d'acide (±)-2-(difluorométhyl)-1-(alcoxycarbonyl)-cyclopropanecarboxylique et d'acide (±)-2-(vinyl)-1-(alcoxycarbonyl)-cyclopropanecarboxylique |
CA3082191C (fr) | 2017-12-07 | 2021-09-21 | Emory University | N4-hydroxycytidine et derives et leurs utilisations anti-virales |
CN111018795B (zh) * | 2019-12-25 | 2023-03-28 | 上海彩迩文生化科技有限公司 | 一种碱性条件下合成喹喔啉-3-酮的方法 |
WO2021209563A1 (fr) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Composés destinés à être utilisés dans le traitement d'infections virales par un coronavirus associé au syndrome respiratoire |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002236591B2 (en) | 2000-12-12 | 2005-07-14 | Schering Corporation | Diaryl peptides as NS3-serine protease inhibitors of hepatits C virus |
AU2002334217B2 (en) | 2001-10-26 | 2008-07-03 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
PL213029B1 (pl) | 2002-05-20 | 2012-12-31 | Bristol Myers Squibb Co | Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie |
PL215228B1 (pl) | 2002-05-20 | 2013-11-29 | Bristol Myers Squibb Co | Zwiazki tripeptydowe, ich zastosowanie i kompozycja farmaceutyczna je zawierajaca oraz jej zastosowanie |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
DE60334205D1 (en) | 2002-05-20 | 2010-10-28 | Bristol Myers Squibb Co | Heterocyclische sulfonamid-hepatitis-c-virus-hemmer |
ES2320771T3 (es) | 2003-04-16 | 2009-05-28 | Bristol-Myers Squibb Company | Inhibidores peptidicos de isoquinolina macrociclicos del virus de la hepatitis c. |
US7176208B2 (en) | 2003-04-18 | 2007-02-13 | Enanta Pharmaceuticals, Inc. | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors |
DE602004023924D1 (en) | 2003-04-18 | 2009-12-17 | Enanta Pharm Inc | Ease-hemmer |
BRPI0410456B8 (pt) | 2003-05-21 | 2021-05-25 | Boehringer Ingelheim Int | compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação |
US7135462B2 (en) | 2003-11-20 | 2006-11-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
PL1778702T3 (pl) | 2004-07-16 | 2011-12-30 | Gilead Sciences Inc | Związki przeciwwirusowe |
WO2007001406A2 (fr) | 2004-10-05 | 2007-01-04 | Chiron Corporation | Composes macrocycliques contenant un aryle |
CA2606195C (fr) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Inhibiteurs de la protease ns3 du vhc |
TWI387603B (zh) | 2005-07-20 | 2013-03-01 | Merck Sharp & Dohme | Hcv ns3蛋白酶抑制劑 |
GEP20105124B (en) | 2005-07-25 | 2010-11-25 | Array Biopharma Inc | Novel macrocyclic inhibitors of hepatitis c virus replication |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
BRPI0614205A2 (pt) | 2005-08-01 | 2016-11-22 | Merck & Co Inc | composto, composição farmacêutica, e, uso de composto |
CN101233148A (zh) * | 2005-08-01 | 2008-07-30 | 默克公司 | 作为hcv ns3蛋白酶抑制剂的大环肽 |
KR20080056295A (ko) | 2005-10-11 | 2008-06-20 | 인터뮨, 인크. | C형 간염 바이러스 복제를 억제하기 위한 화합물 및 방법 |
US7772183B2 (en) | 2005-10-12 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
RU2008152171A (ru) | 2006-07-05 | 2010-08-10 | Интермьюн, Инк. (Us) | Новые ингибиторы вирусной репликации гепатита с |
EP2076278B1 (fr) | 2006-10-24 | 2015-05-06 | Merck Sharp & Dohme Corp. | Inhibiteurs macrocycliques de la protéase HCV NS3 |
JP5345541B2 (ja) | 2006-10-24 | 2013-11-20 | メルク・シャープ・アンド・ドーム・コーポレーション | Hcvns3プロテアーゼ阻害剤 |
CN101583372A (zh) | 2006-10-24 | 2009-11-18 | 默克公司 | Hcv ns3蛋白酶抑制剂 |
EP2083844B1 (fr) | 2006-10-27 | 2013-11-27 | Merck Sharp & Dohme Corp. | Inhibiteurs de protéase ns3 du vhc |
AU2007318165B2 (en) | 2006-10-27 | 2011-11-17 | Msd Italia S.R.L. | HCV NS3 protease inhibitors |
US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20080287449A1 (en) | 2007-04-26 | 2008-11-20 | Deqiang Niu | Aza-tripeptide hepatitis c serine protease inhibitors |
EP2177523A1 (fr) | 2007-05-03 | 2010-04-21 | Intermune, Inc. | Nouveaux inhibiteurs macrocycliques de réplication du virus de l'hépatite C |
AP2009005057A0 (en) | 2007-05-10 | 2009-12-31 | Array Biopharma Inc | Novel peptide inhibitors of hepatitis c virus replication |
US20090005387A1 (en) | 2007-06-26 | 2009-01-01 | Deqiang Niu | Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors |
EP2162432A2 (fr) | 2007-06-29 | 2010-03-17 | Gilead Sciences, Inc. | Composés antiviraux |
KR101596524B1 (ko) | 2007-06-29 | 2016-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 항바이러스 화합물 |
JP5433573B2 (ja) | 2007-07-19 | 2014-03-05 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | 抗ウイルス剤としての大環状化合物 |
WO2009014730A1 (fr) | 2007-07-26 | 2009-01-29 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la sérine protéase |
CA2700383A1 (fr) | 2007-09-24 | 2009-04-02 | Achillion Pharmaceuticals, Inc. | Peptides contenant de l'uree en tant qu'inhibiteurs de la replication virale |
US8106059B2 (en) | 2007-10-24 | 2012-01-31 | Virobay, Inc. | Substituted pyrazines that inhibit protease cathepsin S and HCV replication |
WO2009055335A2 (fr) | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Inhibiteurs des protéases du vhc |
CL2008003384A1 (es) | 2007-11-14 | 2009-12-11 | Enanta Pharm Inc | Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c. |
US8263549B2 (en) | 2007-11-29 | 2012-09-11 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors |
WO2009070689A1 (fr) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | Dérivés de proline bicycliques substitués en c5 en tant qu'inhibiteurs de la protéase ns3 du virus de l'hépatite c |
WO2009073719A1 (fr) | 2007-12-05 | 2009-06-11 | Enanta Pharmaceuticals, Inc. | Dérivés de quinoxalinyle |
US8273709B2 (en) | 2007-12-14 | 2012-09-25 | Enanta Pharmaceuticals, Inc. | Triazole-containing macrocyclic HCV serine protease inhibitors |
US8309685B2 (en) | 2007-12-21 | 2012-11-13 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
US9163061B2 (en) | 2007-12-21 | 2015-10-20 | Celgene Avilomics Research, Inc. | HCV protease inhibitors and uses thereof |
US8293705B2 (en) | 2007-12-21 | 2012-10-23 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
CN102036966A (zh) | 2008-01-24 | 2011-04-27 | 益安药业 | 作为hcv丝氨酸蛋白酶抑制剂的二氟化三肽 |
AR070413A1 (es) | 2008-02-04 | 2010-04-07 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de proteasa de serina |
CA2714604A1 (fr) | 2008-02-25 | 2009-09-03 | Merck Sharp & Dohme Corp. | Inhibiteurs macrocycliques de la protease ns3 du vhc |
WO2009114633A1 (fr) | 2008-03-12 | 2009-09-17 | Virobay, Inc. | Procédé de préparation de dérivés de (3s)-3-amino-n-cyclopropyl-2-hydroxyalcanamide |
WO2009117594A1 (fr) | 2008-03-20 | 2009-09-24 | Enanta Pharmaceuticals, Inc. | Composés macrocycliques fluorés en tant qu'inhibiteurs du virus de l'hépatite c |
AP2010005416A0 (en) | 2008-04-15 | 2010-10-31 | Intermune Inc | Novel macrocyclic inhibitors of hepatitis c virus replication. |
US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2271345B1 (fr) | 2008-04-28 | 2015-05-20 | Merck Sharp & Dohme Corp. | Inhibiteurs de la protéase hcv ns3 |
US8211891B2 (en) | 2008-04-30 | 2012-07-03 | Enanta Pharmaceuticals, Inc. | Difluoromethyl-containing macrocyclic compounds as hepatitis C virus inhibitors |
CA2731177C (fr) | 2008-07-22 | 2013-10-29 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Composes de quinoxaline macrocycliques en tant qu'inhibiteurs de protease ns3 du virus de l'hepatite c (hcv) |
AU2009278075B2 (en) | 2008-08-07 | 2013-07-04 | F. Hoffmann-La Roche Ag | Process for the preparation of a macrocycle |
WO2010021717A2 (fr) | 2008-08-20 | 2010-02-25 | Sequoia Pharmaceuticals, Inc. | Inhibiteurs de la protéase du vhc |
UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
WO2010033466A1 (fr) | 2008-09-16 | 2010-03-25 | Phenomix Corporation | Inhibiteurs macrocycliques de la protéase du virus de l'hépatite c |
EA018603B1 (ru) | 2008-09-16 | 2013-09-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv |
US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US20100080770A1 (en) | 2008-09-29 | 2010-04-01 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CN102216321A (zh) | 2008-10-15 | 2011-10-12 | 因特蒙公司 | 治疗性抗病毒肽 |
WO2010048468A1 (fr) | 2008-10-23 | 2010-04-29 | Concert Pharmaceuticals, Inc. | Inhibiteurs macrocycliques deutériés de la protéase virale ns3 |
EP2350114A1 (fr) | 2008-11-20 | 2011-08-03 | Achillion Pharmaceuticals, Inc. | Composés cycliques de carboxamide et analogues de ceux-ci utilisés comme inhibiteurs du virus de l hépatite c |
JP5553839B2 (ja) | 2008-11-21 | 2014-07-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 経口投与される強力なhcv阻害活性を有する医薬組成物 |
US20100272674A1 (en) | 2008-12-04 | 2010-10-28 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
BRPI0922913A2 (pt) | 2008-12-10 | 2015-08-18 | Achillion Pharmaceuticals Inc | Análogos cíclicos de peptídeo 4-amino-4-oxobutanoil inibidores de replicação viral |
US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
MX2011006631A (es) | 2008-12-19 | 2011-09-06 | Gilead Sciences Inc | Inhibidores de proteasa ns3 del virus hcv. |
CA2745565C (fr) | 2008-12-23 | 2017-03-07 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Procedes et intermediaires pour preparer un inhibiteur macrocyclique de protease du vhc |
CA2761650C (fr) | 2009-05-13 | 2015-05-26 | Enanta Pharmaceuticals, Inc. | Composes macrocycliques comme inhibiteurs du virus de l'hepatite c |
US8703700B2 (en) | 2009-05-22 | 2014-04-22 | Sequoia Pharmaceuticals, Inc. | Bimacrocylic HCV NS3 protease inhibitors |
EP2459582B1 (fr) | 2009-07-30 | 2015-05-27 | Merck Sharp & Dohme Corp. | Inhibiteurs de protéase ns3 du virus de l'hépatite c |
JP2013500961A (ja) | 2009-07-31 | 2013-01-10 | カディラ ヘルスケア リミテッド | グルコキナーゼ(gk)アクチベーターとしての置換ベンズアミド誘導体 |
AU2010286681A1 (en) | 2009-08-27 | 2012-02-09 | Merck Sharp & Dohme Corp. | Processes for preparing protease inhibitors of hepatitis C virus |
JP2013505952A (ja) | 2009-09-28 | 2013-02-21 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新しい大環状阻害剤 |
US20110082182A1 (en) | 2009-10-01 | 2011-04-07 | Intermune, Inc. | Therapeutic antiviral peptides |
TW201119667A (en) | 2009-10-19 | 2011-06-16 | Enanta Pharm Inc | Bismacrocyclic compounds as hepatitis C virus inhibitors |
NZ602288A (en) | 2010-03-10 | 2014-02-28 | Abbvie Bahamas Ltd | Solid compositions comprising amorphous (2r,6s,13as,14ar,16as,z)-n-(cyclopropylsulfonyl)-6-(5-methylpyrazine-2-carboxamido)-5,16-dioxo-2-(phenanthridin-6-yloxy)-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a-carboxamide |
US8530497B2 (en) | 2010-03-11 | 2013-09-10 | Boehringer Ingelheim International Gmbh | Crystalline salts of a potent HCV inhibitor |
MX2012014301A (es) | 2010-06-07 | 2013-04-29 | Enanta Pharm Inc | Inhibidores macrociclicos de serina proteasa de hepatitis c. |
WO2012019299A1 (fr) | 2010-08-11 | 2012-02-16 | Boehringer Ingelheim International Gmbh | Composés inhibiteurs de l'hépatite c |
US20120094897A1 (en) | 2010-09-15 | 2012-04-19 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
EP2618665A4 (fr) | 2010-09-21 | 2014-08-20 | Merck Sharp & Dohme | Inhibiteurs de protéase ns3 du vhc |
AU2011305695B2 (en) | 2010-09-21 | 2016-05-19 | Enanta Pharmaceuticals, Inc. | Macrocyclic proline derived HCV serine protease inhibitors |
US20120095211A1 (en) | 2010-09-22 | 2012-04-19 | Intermune, Inc. | Substituted proline inhibitors of hepatitis c virus replication |
WO2012047764A1 (fr) | 2010-10-04 | 2012-04-12 | Intermune, Inc. | Peptides antiviraux thérapeutiques |
US20120101032A1 (en) | 2010-10-22 | 2012-04-26 | Intermune, Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
MX2013004906A (es) | 2010-11-01 | 2013-12-06 | Genoscience Pharma | Nuevos inhibidores especificos de la proteasa ns3 de hcv. |
JP6034802B2 (ja) | 2010-12-14 | 2016-11-30 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 大環状ラクタムの調製のための方法および中間体 |
CA2822556A1 (fr) | 2010-12-30 | 2012-07-05 | Enanta Pharmaceuticals, Inc | Inhibiteurs macrocycliques de serine protease d'hepatite c |
PE20140039A1 (es) | 2010-12-30 | 2014-03-01 | Enanta Pharm Inc | Inhibidores de serina proteasa de hepatitis c a base de macrociclicos de fenantridina |
US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
EP2726475B1 (fr) | 2011-05-27 | 2017-10-25 | Bristol-Myers Squibb Company | Tripeptides contenant du deuterium comme inhibiteurs du virus de l'hepatite c |
US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
US8962810B2 (en) | 2011-06-16 | 2015-02-24 | AB Pharma Ltd. | Macrocyclic heterocyclic compound for inhibiting hepatitis C virus and preparation and use thereof |
WO2012176149A1 (fr) | 2011-06-23 | 2012-12-27 | Panmed Ltd. | Traitement du virus de l'hépatite c |
AU2012299218A1 (en) | 2011-08-19 | 2014-02-20 | Merck Sharp & Dohme Corp. | Crystal forms of a HCV protease inhibitor |
RU2014122154A (ru) | 2011-10-31 | 2015-12-10 | Мерк Шарп И Доум Корп. | Композиции, пригодные для лечения вирусных заболеваний |
EP2780026B1 (fr) | 2011-11-15 | 2019-10-23 | Merck Sharp & Dohme Corp. | Inhibiteurs de la protéase ns3 du vhc |
EP2802313A1 (fr) | 2012-01-12 | 2014-11-19 | Boehringer Ingelheim International GmbH | Formulations pharmaceutiques stabilisées d'un inhibiteur du vhc puissant |
UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
US9617310B2 (en) | 2013-03-15 | 2017-04-11 | Gilead Sciences, Inc. | Inhibitors of hepatitis C virus |
-
2013
- 2013-02-07 UA UAA201413651A patent/UA119315C2/uk unknown
- 2013-07-02 SI SI201330345A patent/SI2870160T1/sl unknown
- 2013-07-02 US US13/934,090 patent/US9296782B2/en active Active
- 2013-07-02 AR ARP130102368 patent/AR091661A1/es active IP Right Grant
- 2013-07-02 MD MDA20180040A patent/MD20180040A2/ro not_active Application Discontinuation
- 2013-07-02 PT PT137393245T patent/PT2870160T/pt unknown
- 2013-07-02 RS RS20161182A patent/RS55494B1/sr unknown
- 2013-07-02 ME MEP-2019-66A patent/ME03362B/fr unknown
- 2013-07-02 EA EA201492214A patent/EA027390B1/ru unknown
- 2013-07-02 JP JP2015520657A patent/JP6025977B2/ja active Active
- 2013-07-02 KR KR1020197031860A patent/KR20190124346A/ko not_active Application Discontinuation
- 2013-07-02 SG SG10201912269YA patent/SG10201912269YA/en unknown
- 2013-07-02 IN IN2598MUN2014 patent/IN2014MN02598A/en unknown
- 2013-07-02 PE PE2014002587A patent/PE20150204A1/es active IP Right Grant
- 2013-07-02 EA EA201790661A patent/EA033961B1/ru unknown
- 2013-07-02 ES ES18215386T patent/ES2827300T3/es active Active
- 2013-07-02 SG SG11201408739VA patent/SG11201408739VA/en unknown
- 2013-07-02 ES ES16190694T patent/ES2716138T3/es active Active
- 2013-07-02 NZ NZ703064A patent/NZ703064A/en unknown
- 2013-07-02 UY UY0001034888A patent/UY34888A/es not_active Application Discontinuation
- 2013-07-02 NZ NZ739248A patent/NZ739248A/en unknown
- 2013-07-02 MX MX2014015846A patent/MX360597B/es active IP Right Grant
- 2013-07-02 PL PL13739324T patent/PL2870160T3/pl unknown
- 2013-07-02 CA CA2877005A patent/CA2877005C/fr active Active
- 2013-07-02 PT PT16190694T patent/PT3159345T/pt unknown
- 2013-07-02 HU HUE16190694A patent/HUE042345T2/hu unknown
- 2013-07-02 AP AP2014008166A patent/AP3903A/en active
- 2013-07-02 LT LTEP13739324.5T patent/LT2870160T/lt unknown
- 2013-07-02 BR BR122021012378-0A patent/BR122021012378B1/pt active IP Right Grant
- 2013-07-02 EP EP20191299.5A patent/EP3825312A1/fr not_active Withdrawn
- 2013-07-02 ES ES13739324.5T patent/ES2605383T3/es active Active
- 2013-07-02 EP EP18215386.6A patent/EP3492464B1/fr active Active
- 2013-07-02 KR KR1020147037149A patent/KR101610575B1/ko active Protection Beyond IP Right Term
- 2013-07-02 US US14/412,331 patent/US20150175655A1/en not_active Abandoned
- 2013-07-02 TW TW102123626A patent/TWI602822B/zh active
- 2013-07-02 CN CN201380042756.6A patent/CN104540832B/zh active Active
- 2013-07-02 EP EP13739324.5A patent/EP2870160B1/fr active Active
- 2013-07-02 SI SI201331350T patent/SI3159345T1/sl unknown
- 2013-07-02 SG SG10201702950TA patent/SG10201702950TA/en unknown
- 2013-07-02 AU AU2013286729A patent/AU2013286729B2/en active Active
- 2013-07-02 KR KR1020167008636A patent/KR102040023B1/ko active Protection Beyond IP Right Term
- 2013-07-02 BR BR112014033080-8A patent/BR112014033080B1/pt active IP Right Grant
- 2013-07-02 MD MDA20140136A patent/MD4602B1/ro not_active IP Right Cessation
- 2013-07-02 EP EP16190694.6A patent/EP3159345B1/fr active Active
- 2013-07-02 LT LTEP16190694.6T patent/LT3159345T/lt unknown
- 2013-07-02 ME MEP-2016-245A patent/ME02547B/fr unknown
- 2013-07-02 CN CN201610474633.5A patent/CN106117309B/zh active Active
- 2013-07-02 DK DK16190694.6T patent/DK3159345T3/en active
- 2013-07-02 MY MYPI2014003617A patent/MY173342A/en unknown
- 2013-07-02 RS RS20190303A patent/RS58409B1/sr unknown
- 2013-07-02 DK DK13739324.5T patent/DK2870160T3/en active
- 2013-07-02 PL PL16190694T patent/PL3159345T3/pl unknown
- 2013-07-02 WO PCT/US2013/049119 patent/WO2014008285A1/fr active Application Filing
- 2013-07-02 HU HUE13739324A patent/HUE032404T2/en unknown
-
2014
- 2014-12-22 PH PH12014502862A patent/PH12014502862B1/en unknown
- 2014-12-28 IL IL236500A patent/IL236500B/en active IP Right Grant
- 2014-12-31 CL CL2014003634A patent/CL2014003634A1/es unknown
-
2015
- 2015-01-13 CO CO15005727A patent/CO7160104A2/es unknown
- 2015-01-20 EC ECIEPI20152066A patent/ECSP15002066A/es unknown
- 2015-02-03 CR CR20150045A patent/CR20150045A/es unknown
- 2015-10-13 HK HK15109972.6A patent/HK1209416A1/xx unknown
- 2015-11-04 HK HK15110878.9A patent/HK1210151A1/xx unknown
- 2015-11-10 JP JP2015220577A patent/JP2016041743A/ja not_active Withdrawn
-
2016
- 2016-01-13 AU AU2016200201A patent/AU2016200201A1/en not_active Abandoned
- 2016-01-15 US US14/996,961 patent/US20160130300A1/en not_active Abandoned
- 2016-02-03 AU AU2016200670A patent/AU2016200670A1/en not_active Abandoned
- 2016-06-17 US US15/185,273 patent/US9655944B2/en active Active
- 2016-10-12 PH PH12016502040A patent/PH12016502040A1/en unknown
- 2016-10-24 HR HRP20161379TT patent/HRP20161379T1/hr unknown
- 2016-12-22 CY CY20161101337T patent/CY1118379T1/el unknown
- 2016-12-27 SM SM201600470T patent/SMT201600470B/it unknown
-
2017
- 2017-04-14 US US15/488,035 patent/US20170290827A1/en not_active Abandoned
- 2017-05-23 IL IL252446A patent/IL252446A0/en active IP Right Grant
- 2017-06-13 AU AU2017203984A patent/AU2017203984B2/en active Active
-
2018
- 2018-06-11 US US16/005,111 patent/US10335409B2/en active Active
- 2018-06-12 JP JP2018111786A patent/JP2018154651A/ja not_active Withdrawn
- 2018-09-04 IL IL26158118A patent/IL261581B/en active IP Right Grant
- 2018-11-08 MX MX2018013668A patent/MX2018013668A/es unknown
-
2019
- 2019-03-19 CY CY20191100328T patent/CY1121418T1/el unknown
- 2019-03-25 HR HRP20190578TT patent/HRP20190578T1/hr unknown
- 2019-05-10 US US16/409,610 patent/US10603318B2/en active Active
- 2019-08-29 AU AU2019222909A patent/AU2019222909B2/en active Active
- 2019-09-25 IL IL26966219A patent/IL269662A/en unknown
-
2020
- 2020-05-04 PH PH12020550552A patent/PH12020550552A1/en unknown
- 2020-05-15 JP JP2020085702A patent/JP2020143107A/ja active Pending
-
2021
- 2021-06-23 AU AU2021204238A patent/AU2021204238A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
PH12015501996A1 (en) | Heterocyclic compounds and uses thereof | |
IN2015DN01119A (fr) | ||
GEP201706671B (en) | Heterocyclyl compounds as mek inhibitors | |
MX2016006336A (es) | Compuestos pirazolopirimidina. | |
IN2014CN04530A (fr) | ||
PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
UA109010C2 (en) | MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
IN2014MN02652A (fr) | ||
IN2014MN02657A (fr) | ||
NZ703162A (en) | Heterocyclic modulators of lipid synthesis | |
MD20160136A2 (ro) | Compuşi dihidroizochinolinonici substituiţi | |
EA201492287A1 (ru) | Дейтерированные производные руксолитиниба | |
JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
MY186599A (en) | Substituted pyridopyrazines as novel syk inhibitors | |
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
GB201209587D0 (en) | Therapeutic compounds | |
MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil | |
MX2013009386A (es) | Nuevos compuestos de azaespirodecanona. | |
GEP201706675B (en) | Imidazo-triazine derivatives as pde10 inhibitors | |
MX2014009084A (es) | Derivados de pirimidooxazocina como inhibidores de mtor. | |
UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao | |
TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |